Abstract
In their article “The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?” Hartung and colleagues1 describe “alarming” increases in US prices of disease-modifying therapies (DMTs) for persons with relapsing-onset multiple sclerosis (MS). They looked at drug pricing from 1993 to 2013. This review summarizes their findings and discusses the relevance for those with MS.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
